1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The ADDF-Harrington Scholar Program identifies and accelerates promising drug discovery research for Alzheimer's disease and related dementias, with explicit support for AI/ML-enabled approaches including generative AI for novel drug candidate identification, deep learning for target validation, AI-driven repurposing of approved drugs, and computational platforms for amyloid and tau pathology.
Scholars receive a 2-year grant of $600K plus comprehensive drug development expertise from the Harrington Discovery Institute and ADDF's Drug Development Accelerator. Optional follow-on investment through ADDF's venture arm. Strong fit for academic investigators with promising preclinical leads, AI-enabled drug discovery platforms, or novel computational therapeutic approaches.
Get alerted about grants like this
Get emailed when new opportunities from “Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Faculty-level investigators at academic institutions, research nonprofits, and academic medical centers worldwide. Must have novel drug discovery research with clear translational pathway. Industry-only applications not eligible but industry partnerships welcomed. Confirm the full requirements in the official notice before applying.
The current listing shows USD 600,000 over 2 years per scholar plus comprehensive drug development support valued at additional USD 700,000-1,000,000. Total package approximately USD 1,300,000-1,600,000 per awardee. Up to 5 scholars selected per cycle. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for ADDF-Harrington Scholar Program for AI-Enabled Drug Discovery Research in Alzheimer Disease and Related Dementias are due August 15, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
ADDF-Harrington Scholar Program for AI-Enabled Drug Discovery Research in Alzheimer Disease and Related Dementias is funded by Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The John Templeton Foundation's 2026 Online Funding Inquiry (OFI) cycle prioritizes projects exploring intelligences across natural, human, and artificial systems. Funded AI-relevant scope includes the science of intelligence and cognition, philosophical and ethical foundations of AI, comparative intelligence research (human, animal, machine), human flourishing in an AI-mediated world, foundations of trust and value alignment, and AI's implications for meaning, agency, virtue, and religious traditions. Two competitive OFI cycles per year; successful inquiries are invited to submit full proposals.
The Mozilla Foundation Fellows Program supports tomorrow's tech leaders working at the intersection of trustworthy AI, open source, and public interest technology. Mozilla Fellows pursue projects on AI auditing, algorithmic accountability, open source AI infrastructure, AI and democracy, content moderation governance, AI policy research, and bias and harm in machine learning systems. Fellows are embedded with host organizations (universities, NGOs, advocacy groups, news organizations) and receive a stipend plus a network of peers and amplification support. Mozilla has invested over $35 million across the last decade in building a better technology future. The 2026 cohort prioritizes Trustworthy AI and information ecosystem resilience.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleA new Interior Department policy routes every grant and cooperative agreement of $50,000 or more through two political appointees for manual review. The result is a backlog of roughly 1,400 grants and $362 million in delayed funding — up from fewer than 10 two years ago. Here is how the bottleneck works, why it matters even for recipients who already have an award letter, and what nonprofits, universities, states, and tribes should do to protect projects that depend on Interior dollars.
Read articleAs of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read article